Related Experiment Video

Updated: Apr 18, 2026

Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
03:02

Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification

Published on: July 25, 2025

650

Some pharmacokinetics of sevoflurane in a child with severe lipodystrophy

Evi R Steen1, Luc E C De Baerdemaeker, Jurgen Van Limmen

  • 1From the Department of Anesthesiology, University Hospital Ghent, Ghent, Belgium.

A & a Case Reports
|January 23, 2015
PubMed

Insights

Sevoflurane anesthesia in a child with lipodystrophy was affected by high triglyceride levels and low body fat. Managing hypertriglyceridemia improved sevoflurane pharmacokinetics.

Area of Science:

  • Anesthesiology
  • Pediatric Endocrinology
  • Pharmacokinetics

Background:

  • Lipodystrophies involve adipose tissue loss and hypertriglyceridemia.
  • These metabolic alterations can impact drug handling.
  • Understanding these effects is crucial for patient safety.

Purpose of the Study:

  • To report the impact of sevoflurane anesthesia in a child with lipodystrophy.
  • To illustrate how hypertriglyceridemia and fat loss affect sevoflurane pharmacokinetics.
  • To highlight the importance of managing metabolic derangements before anesthesia.

Main Methods:

  • Case report of a child with lipodystrophy undergoing sevoflurane anesthesia.
  • Administration of sevoflurane before and after correction of hypertriglyceridemia.
  • Pharmacokinetic assessment of sevoflurane in both conditions.

Main Results:

  • Sevoflurane pharmacokinetics differed significantly before and after hypertriglyceridemia correction.
  • Increased serum lipids and reduced fat stores altered sevoflurane distribution and elimination.
  • Anesthesia management requires consideration of these physiological changes.

Conclusions:

  • Lipodystrophy and associated hypertriglyceridemia markedly influence sevoflurane pharmacokinetics.
  • Correction of severe hypertriglyceridemia improved sevoflurane handling.
  • This case underscores the need for tailored anesthetic approaches in patients with metabolic disorders.

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.3K
In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells04:56

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

Published on: October 23, 2018

7.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
513
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
886
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
371
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
929